These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 3904441)

  • 21. Timing optimizes sustained-release indomethacin treatment of osteoarthritis.
    Levi F; Le Louarn C; Reinberg A
    Clin Pharmacol Ther; 1985 Jan; 37(1):77-84. PubMed ID: 3880688
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic profile of a new sustained-release theophylline pellet formulation for once-daily evening administration.
    Steinijans VW; Sauter R; Böhm A; Staudinger H
    Arzneimittelforschung; 1988 Aug; 38(8A):1241-50. PubMed ID: 3190813
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetic characteristics of a new multiple unit sustained release formulation of sodium valproate.
    Wangemann M; Retzow A; Vens-Cappell B
    Int J Clin Pharmacol Ther; 1999 Feb; 37(2):100-8. PubMed ID: 10082174
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics and tolerance of slow-release indomethacin tablets in rheumatoid arthritis.
    Kaarela K; Lehtinen K; Mäkisara P; Holttinen K; Lamminsivu U; Gordin A
    Eur J Clin Pharmacol; 1982 Oct; 23(4):349-51. PubMed ID: 7173304
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Disposition, intestinal absorption and drug metabolizing enzyme activities after multiple doses of indomethacin in rat and effect of antacid and dicyclomine on the parameters.
    Ogiso T; Iwaki M; Tamaki E
    J Pharmacobiodyn; 1982 Oct; 5(10):760-70. PubMed ID: 7161704
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Indomethacin kinetics and urinary excretion of prostaglandin E2 following oral administration of various dosage forms of indomethacin].
    Düsing R; Dittrich P; Kukovetz WR; Lehmann K; Kramer HJ
    Z Rheumatol; 1983; 42(4):235-41. PubMed ID: 6580789
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Osmosin: its effect on plasma and synovial fluid kinetics of indomethacin.
    Fowler PD; Dawes PT
    Eur J Clin Pharmacol; 1985; 27(6):689-91. PubMed ID: 3987775
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The metabolism of indomethacin in man.
    Duggan DE; Hogans AF; Kwan KC; McMahon FG
    J Pharmacol Exp Ther; 1972 Jun; 181(3):563-75. PubMed ID: 4555898
    [No Abstract]   [Full Text] [Related]  

  • 30. Bioequivalence of a new sustained-release formulation of sodium valproate, valproate modified-release granules, compared with existing sustained-release formulations after once- or twice-daily administration.
    Dulac O; Alvarez JC
    Pharmacotherapy; 2005 Jan; 25(1):35-41. PubMed ID: 15767218
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of oral and intravenous indomethacin in preterm infants.
    Bhat R; Vidyasagar D; Fisher E; Hastreiter A; Ramirez JL; Burns L; Evans M
    Dev Pharmacol Ther; 1980; 1(2-3):101-10. PubMed ID: 6927543
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bioavailability of indomethacin tablets in men volunteers.
    Groth PE; Dunn JM
    Clin Pharm; 1986 Oct; 5(10):820-4. PubMed ID: 3780150
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparison of oral and intravenous indomethacin dispositions in the premature infant with patent ductus arteriosus.
    Evans M; Bhat R; Vidyasagar D; Patel M; Hastreiter A
    Pediatr Pharmacol (New York); 1981; 1(3):251-8. PubMed ID: 7346745
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of meals and dosage-form modification on theophylline bioavailability from a 24-hour sustained-release delivery system.
    González MA; Straughan AB
    Clin Ther; 1994; 16(5):804-14. PubMed ID: 7859239
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The evolution of precision drug delivery.
    Heimlich KR
    Curr Med Res Opin; 1983; 8 Suppl 2():28-37. PubMed ID: 6851623
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The interaction between indomethacin and probenecid. A clinical and pharmacokinetic study.
    Baber N; Halliday L; Sibeon R; Littler T; Orme ML
    Clin Pharmacol Ther; 1978 Sep; 24(3):298-307. PubMed ID: 688724
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia.
    McKeage K; Plosker GL
    Drugs; 2002; 62(4):633-53. PubMed ID: 11893233
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Studies on sustained-release dosage forms. I. Preparation and bioavailability of indomethacin suppositories.
    Umeda T; Matsuzawa A; Yokoyama T; Kuroda K; Kuroda T
    Chem Pharm Bull (Tokyo); 1983 Aug; 31(8):2793-8. PubMed ID: 6652823
    [No Abstract]   [Full Text] [Related]  

  • 39. A clinical and pharmacokinetic study of indomethacin in standard and slow release formulations.
    Adams KR; Halliday LD; Sibeon RG; Baber N; Littler T; Orme ML
    Br J Clin Pharmacol; 1982 Aug; 14(2):286-9. PubMed ID: 7104182
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sensitive high-performance liquid chromatographic determination of indomethacin in human plasma. Pharmacokinetic studies after single oral dose.
    Astier A; Renat B
    J Chromatogr; 1982 Dec; 233():279-88. PubMed ID: 7161339
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.